Pier Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Pier Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-287	Closed	-$48K	–	154
2014 Q3	$48K	Buy	+287	New	+$47.1K	0.01%	134

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pier Capital's ALXN Position: Q4 2014 in Review

Pier Capital sold out of Alexion Pharmaceuticals (ALXN) in Q4 2014, closing a stake of 287 shares — an estimated $48K sold.

Pier Capital first reported a position in ALXN in Q3 2014 and held it in 1 quarter. The position peaked at $48K in Q3 2014. 578 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

Pier Capital reported no remaining Alexion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Pier Capital sold 287 Alexion Pharmaceuticals shares in Q4 2014, an estimated $48K.
Pier Capital first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 1 quarter.
Pier Capital's Alexion Pharmaceuticals position peaked at $48K in Q3 2014.
578 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Pier Capital's 13F filing for Q4 2014, filed 10 Feb 2015.